Table 5 Trial sponsor for repurposed agents by phase of drug development (as of February 27, 2020)
From: Repurposed agents in the Alzheimer’s disease drug development pipeline
Sponsor | Phase I | Phase II | Phase III | Total (%) |
|---|---|---|---|---|
Academic Medical Centers | 6 | 14 | 4 | 24 (45.3) |
Biopharma | 0 | 2 | 3 | 5 (9.4) |
NIH | 1 | 0 | 0 | 1 (1.9) |
NIH and Academic Medical Centers | 0 | 4 | 2 | 6 (11.3) |
NIH and consortium | 0 | 1 | 0 | 1 (1.9) |
NIH and Industry | 0 | 0 | 1 | 1 (1.9) |
Academic Medical Centers and Industry | 0 | 2 | 0 | 2 (3.8) |
Academic Medical Centers and Foundation | 1 | 4 | 0 | 5 (9.4) |
Academic Medical Centers, Industry, and NIH | 0 | 0 | 1 | 1 (1.9) |
Other combinations | 1 | 4 | 0 | 5 (9.4) |
Other federal sources | 0 | 1 | 1 | 2 (3.8) |
Total | 9 | 32 | 12 | 53 (100.0) |